Date: 2012-01-23
Type of information: Fundraising
Company: Prosensa (The Netherlands)
Investors: New Enterprise Associates (USA)
Abingworth (UK)
Life Sciences Partners (The Netherlands)
Gimv (Belgium)
Idinvest Partners (France)
MedSciences Capital (The Netherlands)
Amount: €23 Million
Funding type: equity financing
Planned used: The fundraising will enable Prosensa to advance its portfolio of RNA-modulating therapeutics for the treatment of rare diseases, including Duchenne muscular dystrophy (DMD), Myotonic Dystrophy (DM1) and Huntington’s disease (HD). The company has advanced the development of five additional compounds in DMD and have announced preclinical testing for a compound for DM1.
Others: Prosensa has raised €23 million in new equity financing. The financing was led by new investor New Enterprise Associates (NEA) and was supported by existing Prosensa investors, Abingworth, Life Sciences Partners, Gimv, Idinvest Partners and MedSciences Capital. David Mott, General Partner of NEA, will join Prosensa’s Supervisory Board.
Therapeutic area: Rare diseases - Genetic diseases
